Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01742793 · ClinicalTrials.gov registry record · Phase 1
An Open Label, International, Multi-centre, Phase I/IIa Study of Lenalidomide (Revlimid) and Romidepsin (Istodax) for Relapsed /Refractory Hodgkin Lymphoma, Mature T-cell Lymphoma and Multiple Myeloma. (RId Study)
A Phase 1 study, sponsored by Yale University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT01742793 is a Phase 1 study that was terminated before completion, run by Yale University. The registered enrollment target is 12 participants.
The verdict
NCT01742793, a Phase 1 study, was terminated before completion, sponsored by Yale University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
The study hypothesis is that lenalidomide and romidepsin (and dexamethasone for patients with myeloma) will have an acceptable toxicity profile and that in combination will have sufficient activity in the target population (including those previously refractory to HDACi monotherapy) to warrant further investigation.
Interventions
- DRUG lenalidomide (Revlimid) and romidepsin (Istodax)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2012-10 |
| Est. Completion | 2016-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01742793
The ClinicalTrials.gov registry entry for NCT01742793 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which lenalidomide (Revlimid) and romidepsin (Istodax) is the first listed.
NCT01742793 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01742793 about?
NCT01742793 is a clinical study titled "An Open Label, International, Multi-centre, Phase I/IIa Study of Lenalidomide (Revlimid) and Romidepsin (Istodax) for Relapsed /Refractory Hodgkin Lymphoma, Mature T-cell Lymphoma and Multiple Myeloma. (RId Study)". The study hypothesis is that lenalidomide and romidepsin (and dexamethasone for patients with myeloma) will have an acceptable toxicity profile and that in combination will have sufficient activity in the target population (including those previously refractory to HDACi monotherapy) to warrant furth...
What is the current status of trial NCT01742793?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2012-10. Estimated completion is 2016-08.
What interventions are being tested in trial NCT01742793?
The interventions under investigation include: lenalidomide (Revlimid) and romidepsin (Istodax) (DRUG).
Who is sponsoring clinical trial NCT01742793?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.